NCT02417103

Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid

Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: Universitätsklinikum Hamburg-Eppendorf · Academic / Other
• Sex: All
• Age: 18 Years – 77 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to investigate the effect of the treatment with the GLP-1 Analogon Liraglutide on the lipid metabolism an inflammation in adipose tissue.

Detailed description

The aim of this study is to investigate the effect of the treatment with the GLP-1 Analogon Liraglutide on the lipid metabolism an inflammation in adipose tissue. As GLP-1 is presumed to improve insulin sensitivity and associated parameters the investigators hypothesize that this might be due to changes in lipid metabolism which might be involved in the regulation of insulin sensitivity. Therefore the investigators intend to investigate changes of metabolic pathways before and after treatment with the GLP-1 analog liraglutide that could play a crucial role in pathogenesis as well as regulation of insulin sensitivity and atherogenic dyslipidemia such as: de novo lipogenesis and reverse cholesterol transport

Conditions

• Obesity

Interventions

Type	Name	Description
DRUG	GLP-1 (Liraglutide)	GLP-1 Analogon
DRUG	Placebo	Placebo

Timeline

• Start date: 2011-12-01
• Primary completion: 2016-09-01
• Completion: 2016-12-01
• First posted: 2015-04-15
• Last updated: 2022-06-30

Locations

1 site across 1 country: Germany